Cargando…
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
OBJECTIVE: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. Th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Psiquiatria
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781714/ https://www.ncbi.nlm.nih.gov/pubmed/30328956 http://dx.doi.org/10.1590/1516-4446-2017-0015 |
_version_ | 1783457425881300992 |
---|---|
author | Linares, Ila M. Zuardi, Antonio W. Pereira, Luis C. Queiroz, Regina H. Mechoulam, Raphael Guimarães, Francisco S. Crippa, José A. |
author_facet | Linares, Ila M. Zuardi, Antonio W. Pereira, Luis C. Queiroz, Regina H. Mechoulam, Raphael Guimarães, Francisco S. Crippa, José A. |
author_sort | Linares, Ila M. |
collection | PubMed |
description | OBJECTIVE: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. The objective of this study was to compare the acute effects of different doses of CBD and placebo in healthy volunteers performing a simulated public speaking test (SPST), a well-tested anxiety-inducing method. METHOD: A total of 57 healthy male subjects were allocated to receive oral CBD at doses of 150 mg (n=15), 300 mg (n=15), 600 mg (n=12) or placebo (n=15) in a double-blind procedure. During the SPST, subjective ratings on the Visual Analogue Mood Scale (VAMS) and physiological measures (systolic and diastolic blood pressure, heart rate) were obtained at six different time points. RESULTS: Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS scores were observed between groups receiving CBD 150 mg, 600 mg and placebo. CONCLUSION: Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves. Optimal therapeutic doses of CBD should be rigorously determined so that research findings can be adequately translated into clinical practice. |
format | Online Article Text |
id | pubmed-6781714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Associação Brasileira de Psiquiatria |
record_format | MEDLINE/PubMed |
spelling | pubmed-67817142019-10-25 Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test Linares, Ila M. Zuardi, Antonio W. Pereira, Luis C. Queiroz, Regina H. Mechoulam, Raphael Guimarães, Francisco S. Crippa, José A. Braz J Psychiatry Original Article OBJECTIVE: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. The objective of this study was to compare the acute effects of different doses of CBD and placebo in healthy volunteers performing a simulated public speaking test (SPST), a well-tested anxiety-inducing method. METHOD: A total of 57 healthy male subjects were allocated to receive oral CBD at doses of 150 mg (n=15), 300 mg (n=15), 600 mg (n=12) or placebo (n=15) in a double-blind procedure. During the SPST, subjective ratings on the Visual Analogue Mood Scale (VAMS) and physiological measures (systolic and diastolic blood pressure, heart rate) were obtained at six different time points. RESULTS: Compared to placebo, pretreatment with 300 mg of CBD significantly reduced anxiety during the speech. No significant differences in VAMS scores were observed between groups receiving CBD 150 mg, 600 mg and placebo. CONCLUSION: Our findings confirm the anxiolytic-like properties of CBD and are consonant with results of animal studies describing bell-shaped dose-response curves. Optimal therapeutic doses of CBD should be rigorously determined so that research findings can be adequately translated into clinical practice. Associação Brasileira de Psiquiatria 2018-10-11 /pmc/articles/PMC6781714/ /pubmed/30328956 http://dx.doi.org/10.1590/1516-4446-2017-0015 Text en http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Linares, Ila M. Zuardi, Antonio W. Pereira, Luis C. Queiroz, Regina H. Mechoulam, Raphael Guimarães, Francisco S. Crippa, José A. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test |
title | Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test |
title_full | Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test |
title_fullStr | Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test |
title_full_unstemmed | Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test |
title_short | Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test |
title_sort | cannabidiol presents an inverted u-shaped dose-response curve in a simulated public speaking test |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781714/ https://www.ncbi.nlm.nih.gov/pubmed/30328956 http://dx.doi.org/10.1590/1516-4446-2017-0015 |
work_keys_str_mv | AT linaresilam cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest AT zuardiantoniow cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest AT pereiraluisc cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest AT queirozreginah cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest AT mechoulamraphael cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest AT guimaraesfranciscos cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest AT crippajosea cannabidiolpresentsaninvertedushapeddoseresponsecurveinasimulatedpublicspeakingtest |